Herr Amy E. 4
4 · BIO-TECHNE Corp · Filed Feb 5, 2026
Research Summary
AI-generated summary of this filing
Bio-Techne (TECH) Director Amy Herr Exercises Options, Pays Tax Withholding
What Happened
- Amy E. Herr, a director of Bio-Techne Corp (TECH), executed derivative transactions on 2026-02-03. She exercised/converted a derivative position that resulted in 38 shares acquired at $0.00 and also had 38 derivative shares disposed (conversion/settlement). Separately, 16 shares were disposed to satisfy a tax liability at $64.63 per share, generating $1,034 in withholding. Overall, the transactions result in a net decline of 16 shares held by Herr (38 acquired − 38 disposed − 16 withheld = −16).
Key Details
- Date: 2026-02-03; Form 4 filed: 2026-02-05 (appears timely).
- Transactions:
- M (exercise/conversion): 38 shares acquired @ $0.00 (total $0).
- F (payment of exercise price/tax withholding): 16 shares disposed @ $64.63 = $1,034.
- M (exercise/conversion – recorded as disposed): 38 shares disposed @ $0.00.
- Net effect: decrease of 16 shares.
- Shares owned after the transaction: not specified in the provided excerpt of the filing.
- Footnotes/notes: the F-coded disposition reflects tax withholding to satisfy withholding obligations. The filing includes multiple footnotes about vesting schedules for awards and options (see the filing for details).
Context
- The pattern (exercise/conversion combined with a small number of shares withheld/surrendered) is typical of option/RSU vesting or conversion where shares are used to cover taxes rather than a market-directed sale. The cash proceeds reported were $1,034 from the 16-share tax withholding. These transactions are usually routine compensation-related actions and should not be interpreted as a market timing signal.
Insider Transaction Report
Form 4
BIO-TECHNE CorpTECH
Herr Amy E.
Director
Transactions
- Exercise/Conversion
Common Stock
2026-02-03+38→ 2,192 total(indirect: By significant other) - Tax Payment
Common Stock
2026-02-03$64.63/sh−16$1,034→ 2,176 total(indirect: By significant other) - Exercise/Conversion
Restricted Stock Units
[F7][F10]2026-02-03−38→ 77 total(indirect: By significant other)→ Common Stock (38 underlying)
Holdings
- 2,680
Common Stock
- 2,415
Stock Option (Right to Buy)
Exercise: $72.05From: 2025-10-24Exp: 2035-02-03→ Common Stock (2,415 underlying) - 3,777
Stock Option (Right to Buy)
[F1]Exercise: $60.96Exp: 2035-10-30→ Common Stock (3,777 underlying) - 6,636(indirect: By significant other)
Stock Option (Right to Buy)
[F2]Exercise: $47.60Exp: 2026-08-07→ Common Stock (6,636 underlying) - 4,472(indirect: By significant other)
Stock Option (Right to Buy)
[F2]Exercise: $66.97Exp: 2027-08-05→ Common Stock (4,472 underlying) - 2,076(indirect: By significant other)
Stock Option (Right to Buy)
[F2]Exercise: $120.46Exp: 2028-08-06→ Common Stock (2,076 underlying) - 2,104(indirect: By significant other)
Stock Option (Right to Buy)
[F3]Exercise: $94.52Exp: 2029-08-15→ Common Stock (2,104 underlying) - 1,084(indirect: By significant other)
Stock Option (Right to Buy)
[F4]Exercise: $84.61Exp: 2030-08-15→ Common Stock (1,084 underlying) - 1,468(indirect: By significant other)
Stock Option (Right to Buy)
[F5]Exercise: $74.91Exp: 2034-08-15→ Common Stock (1,468 underlying) - 344(indirect: By significant other)
Stock Option (Right to Buy)
[F6]Exercise: $72.05Exp: 2035-02-03→ Common Stock (344 underlying) - 118(indirect: By significant other)
Restricted Stock Units
[F7][F8]→ Common Stock (118 underlying) - 320(indirect: By significant other)
Restricted Stock Units
[F7][F9]→ Common Stock (320 underlying) - 932(indirect: By significant other)
Restricted Stock Units
[F7][F11]→ Common Stock (932 underlying) - 2,735(indirect: By significant other)
Stock Option (Right to Buy)
[F12]Exercise: $53.60Exp: 2035-08-15→ Common Stock (2,735 underlying)
Footnotes (12)
- [F1]This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
- [F10]38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028.
- [F11]311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.
- [F12]Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.
- [F2]Fully vested.
- [F3]Options to purchase 528 shares vest on 8/15/2023 and 8/15/2025; and options to purchase 524 shares vest on 8/15/2024 and 8/15/2026.
- [F4]Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
- [F5]Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
- [F6]Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.
- [F7]Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- [F8]118 restricted stock units vest on 8/15/2026.
- [F9]160 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
Signature
/s/ Andrew Nick as Attorney-in-Fact for Amy E. Herr pursuant to Power of Attorney previously filed|2026-02-05